Stereotactic body radiation therapy for the treatment of a post-chemotherapy remnant lung mass in extensive-stage small-cell lung cancer: A case report

  • Authors:
    • Seung‑Gu Yeo
    • Min‑Jeong Kim
  • View Affiliations

  • Published online on: May 18, 2016     https://doi.org/10.3892/etm.2016.3359
  • Pages: 1185-1188
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Stereotactic body radiation therapy (SBRT) can significantly improve the treatment outcomes of patients with inoperable stage I non-small-cell lung cancer. Similarly, a few case studies have reported the effectiveness of SBRT for stage I small-cell lung cancer (SCLC). However, no study has investigated the use of SBRT for extensive‑stage SCLC (ES-SCLC). Compared with conventional RT, SBRT is able to deliver a higher radiation dose precisely and safely to small targets in short‑duration treatments. The present study reports the outcome of a patient with ES‑SCLC who responded favorably to initial chemotherapy and received SBRT for a residual mass in the peripheral lung. A 62‑year‑old female presented with pathologically determined SCLC at clinical stage T4N3M0‑T4 as separate tumor nodules were present in different ipsilateral lobes. The patient received 6 cycles of standard chemotherapy with cisplatin and etoposide. The response of the patient to chemotherapy was evaluated using contrast‑enhanced chest computed tomography and 18F‑fluorodeoxyglucose positron emission tomography‑computed tomography. The only suspected residual viable tumor was a 1.5‑cm mass in the right upper lobe. Targeting this mass, intensity‑modulated SBRT was performed with 48 Gy in 4 fractions and 6 MV photons. In addition, prophylactic cranial irradiation was conducted with 25 Gy in 10 fractions. The patient is alive with no evidence of disease 4 years after treatment. SBRT toxicity was limited to radiation pneumonitis or fibrosis without pulmonary symptoms. This case report suggests the efficacy of SBRT in select ES-SCLC patients with small residual lung disease following chemotherapy.
View Figures
View References

Related Articles

Journal Cover

August-2016
Volume 12 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yeo SG and Yeo SG: Stereotactic body radiation therapy for the treatment of a post-chemotherapy remnant lung mass in extensive-stage small-cell lung cancer: A case report. Exp Ther Med 12: 1185-1188, 2016
APA
Yeo, S., & Yeo, S. (2016). Stereotactic body radiation therapy for the treatment of a post-chemotherapy remnant lung mass in extensive-stage small-cell lung cancer: A case report. Experimental and Therapeutic Medicine, 12, 1185-1188. https://doi.org/10.3892/etm.2016.3359
MLA
Yeo, S., Kim, M."Stereotactic body radiation therapy for the treatment of a post-chemotherapy remnant lung mass in extensive-stage small-cell lung cancer: A case report". Experimental and Therapeutic Medicine 12.2 (2016): 1185-1188.
Chicago
Yeo, S., Kim, M."Stereotactic body radiation therapy for the treatment of a post-chemotherapy remnant lung mass in extensive-stage small-cell lung cancer: A case report". Experimental and Therapeutic Medicine 12, no. 2 (2016): 1185-1188. https://doi.org/10.3892/etm.2016.3359